Verrica Pharma Relocates HQ, Hints at Officer/Director Changes
Ticker: VRCA · Form: 8-K · Filed: Dec 9, 2024 · CIK: 1660334
| Field | Detail |
|---|---|
| Company | Verrica Pharmaceuticals Inc. (VRCA) |
| Form Type | 8-K |
| Filed Date | Dec 9, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $250,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-changes, filing-update
TL;DR
Verrica Pharma moved its HQ and might be shuffling execs/board.
AI Summary
Verrica Pharmaceuticals Inc. announced on December 4, 2024, a change in its principal executive offices to 44 W. Gay St., Suite 400, West Chester, PA 19380. This filing also indicates potential changes related to the departure of directors, election of directors, appointment of officers, and compensatory arrangements for certain officers, though specific details are not provided in this excerpt.
Why It Matters
A change in principal executive offices can signal operational shifts or cost-saving measures. Potential changes in leadership or compensation structures warrant investor attention.
Risk Assessment
Risk Level: medium — The filing mentions potential changes in directors and officers, which can introduce uncertainty regarding company strategy and stability.
Key Numbers
- 001-38529 — SEC File Number (Identifies the company's filing history with the SEC.)
- 46-3137900 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Verrica Pharmaceuticals Inc. (company) — Registrant
- December 4, 2024 (date) — Date of earliest event reported
- 44 W. Gay St., Suite 400, West Chester, PA 19380 (location) — New Principal Executive Offices
- Delaware (location) — State of Incorporation
FAQ
What is the new address for Verrica Pharmaceuticals Inc.'s principal executive offices?
The new address for Verrica Pharmaceuticals Inc.'s principal executive offices is 44 W. Gay St., Suite 400, West Chester, PA 19380.
On what date was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on December 4, 2024.
In which state is Verrica Pharmaceuticals Inc. incorporated?
Verrica Pharmaceuticals Inc. is incorporated in Delaware.
What is Verrica Pharmaceuticals Inc.'s SEC file number?
Verrica Pharmaceuticals Inc.'s SEC file number is 001-38529.
What are the general categories of information covered by Item Information in this filing?
The Item Information in this filing covers Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; and Financial Statements and Exhibits.
Filing Stats: 1,389 words · 6 min read · ~5 pages · Grade level 11 · Accepted 2024-12-09 16:10:00
Key Financial Figures
- $250,000 — z will receive an annual base salary of $250,000 per year, subject to review and adjustm
Filing Documents
- d878105d8k.htm (8-K) — 33KB
- d878105dex101.htm (EX-10.1) — 25KB
- d878105dex102.htm (EX-10.2) — 4KB
- g878105g1207001426006.jpg (GRAPHIC) — 3KB
- 0001193125-24-273406.txt ( ) — 199KB
- vrca-20241204.xsd (EX-101.SCH) — 3KB
- vrca-20241204_lab.xml (EX-101.LAB) — 18KB
- vrca-20241204_pre.xml (EX-101.PRE) — 11KB
- d878105d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 10.1 Offer Letter, dated December 5, 2024, by and between the Company and David Zawitz 10.2 Amendment to 2024 Inducement Plan 104 Cover Page Interactive Data File (formatted as inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Verrica Pharmaceuticals Inc. Date: December 9, 2024 /s/ John J. Kirby John J. Kirby Interim Chief Financial Officer